TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26416653
Drug: telapravir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telapravir (TVR) in combination with pegylated interferon and ribavirin (PegIFN/R)
Study: 24640205
Drug: Badriphal (Hippophae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Badriphal (Hippophae rhamnoides) 350 mg twice daily for 3 months
Study: 17852127
Drug: Open-label stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label stimulant medication
Study: 16824073
Drug: CH100 (Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH100 (Chinese herbal therapy)
Study: 14616189
Drug: Tiagabine 12
Normalized name: tiaGABine 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 12 mg/day
Study: 14616189
Drug: Active medications
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medications (Tiagabine 12 mg/day and 24 mg/day)
Study: 21207091
Drug: EAC (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAC (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all b.i.d. for 8 days)
Study: 21207091
Drug: EACL (EAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: EACL (EAC plus Lactobacillus acidophilus, 5 × 10(9) organisms per capsule, 3 + 2 i.d. for 8 days)
Study: 15577587
Drug: Post-injection transmission-based
Normalized name: post oak pollen extract Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-injection transmission-based segmented attenuation correction (SAC) technique
Study: 31669562
Drug: Clonidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (both doses)
Study: 23464930
Drug: Low-dose SPAA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SPAA (5/10 or 10/10 mg)
Study: 20010119
Drug: Spirulina (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (6 g x d(‐1))
Study: 16860045
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (DMPA) 150 mg/mL
Study: 9010008
Drug: Suramin administered
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin administered intravenously in escalating dosages (300, 350, and 400 micrograms ml-1)
Study: 9010008
Drug: Suramin administered
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin administered intravenously in escalating dosages (350 and 400 micrograms ml-1)
Study: 9010008
Drug: Suramin administered
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin administered intravenously with neurological monitoring
Study: 9010008
Drug: Suramin with
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin with drug discontinuation and plasmapheresis
Study: 1509986
Drug: AM3 (glycophosphopeptide),
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM3 (glycophosphopeptide), 1 g daily for 4 months
Study: 30292481
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of 12 natural lytic anti‐Pseudomonas aeruginosa bacteriophages (PP1131; 1 × 106 PFU/mL) applied as a daily topical treatment for 7 days.
Study: 30292481
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (1% sulfadiazine silver emulsion cream) applied as a daily topical treatment for 7 days.
Study: 30292481
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (1% sulfadiazine silver emulsion cream).
Study: 27739232
Drug: Intramuscular bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bolus injections of 30 mg of ketorolac tromethamine every 6 hours (total daily dose of 120 mg)
Study: 26770927
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy (n=58)
Study: 11251350
Drug: Extended out‐of‐hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended out‐of‐hospital prophylaxis with low‐molecular‐weight heparin
Study: 8348279
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone and lignocaine
Study: 30350406
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention combining health systems navigation and psychosocial counselling for early engagement of antiretroviral therapy (ART) and substance use treatment for PWID living with HIV.
Study: 12766095
Drug: Monthly remunerated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly remunerated routine chiropodist care (n = 47)
Study: 8844033
Drug: Diazepam loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam loading dose therapy (40 to 210 mg, mean 86.9 ± 47.2 mg)
Study: 8844033
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (diazepam and other psychotropic drugs in divided doses)
Study: 6345501
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to 120 mg per day)
Study: 22811410
Drug: Cisplatin 7
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 7 mg/m² Days 1-5, 8-12, 29-33 and 36-40 and 5-fluorouracil 250 mg/m² Days 1-14 and 29-42 with the same radiotherapy (arm B)
Study: 19069889
Drug: Oxytocin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (6 mu min(‐1) infusion)
Study: 16245968
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/mL for 5 min)
Study: 12081834
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg/d)
Study: 8583134
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of interferon alfa‐2b thrice weekly for 6 months
Study: 8583134
Drug: 5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million units of interferon alfa‐2b thrice weekly for 6 months
Study: 8583134
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of interferon alfa‐2b thrice weekly for 2 years
Study: 8583134
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years treatment
Study: 8583134
Drug: Injecting drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injecting drug use
Study: 8583134
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years treatment vs 6 months treatment
Study: 30513252
Drug: DTaP‐IPV‐HB‐PRPT primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV‐HB‐PRPT primary and booster vaccination with birth dose of HB
Study: 30513252
Drug: DTaP‐IPV‐HB‐PRPT primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV‐HB‐PRPT primary and booster vaccination without birth dose of HB
Study: 21542734
Drug: 1% alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% alendronate gel
Study: 14597353
Drug: Higher total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher total dose irradiation or prophylactic surgery
Study: 28143564
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered within 3 hours of injury
Study: 28143564
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered after 3 hours of injury
Study: 28143564
Drug: Subgroup analyses
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analyses for early TXA treatment
Study: 28143564
Drug: Subgroup analyses
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analyses for late TXA treatment
Study: 23022602
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein yogurt snack (24 g protein)
Study: 23022602
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein yogurt snack (14 g protein)
Study: 23022602
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein yogurt snack (5 g protein)
Study: 20671652
Drug: Low-dose atorvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose atorvastatin, titrated to maintain LDL cholesterol <100 mg/dL
Study: 17989103
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at 2 g/day for 6 months along with prednisolone at 0.5 mg/kg/day for 2-3 months
Study: 17989103
Drug: Conventional therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy: prednisolone 1 mg/kg/day for 3-6 months for FSGS and alternating monthly cycles of steroids and cyclophosphamide for 6 months for MN
Study: 10540048
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Alpha2b‐interferon + ketoprofen 200 mg/day five times weekly)
Study: 8551786
Drug: Nafamostat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat (2 mg/kg per hour) during cardiopulmonary bypass
Study: 24206588
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) monotherapy
Study: 12417888
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg
Study: 9350366
Drug: Nicardipine (0.017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.017 mg.kg‐1) with isoflurane
Study: 9350366
Drug: Nicardipine (0.017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.017 mg.kg‐1) with enflurane
Study: 8186346
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg b.d.
Study: 7986969
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg q.d.s.
Study: 1486156
Drug: Ranitidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 600 mg b.d.
Study: 31779697
Drug: PG102P 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG102P 1.5 g/day
Study: 17179242
Drug: Intraoperative cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display and treatment intervention protocol (n = 100)
Study: 15369567
Drug: Outpatient chemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient chemical dependency treatment
Study: 14607566
Drug: Ketoconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (50 mg every 48 hours) with hMG
Study: 8580277
Drug: Fluconazole oral
Normalized name: fluconazole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole oral suspension
Study: 8877335
Drug: Ulfon Lyoc
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulfon Lyoc and Ulfon suspension
Study: 6356322
Drug: Sucralfate 500
Normalized name: sucralfate 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 500 mg before breakfast, lunch, supper and 1000 mg on retiring
Study: 3083505
Drug: Auranofin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (6 mg/day)
Study: 10468203
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg once daily
Study: 20064022
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum ointment
Study: 28027682
Drug: Achillea millefolium
Normalized name: ACHILLEA MILLEFOLIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea millefolium ointment
Study: 1124717
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg/day
Study: 12655535
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (Group A)
Study: 8648360
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 500 mg twice daily
Study: 1498502
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant preparation (SF‐RI 1)
Study: 15110926
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol infusion
Study: 31735560
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg plus dexamethasone 40 mg
Study: 22617578
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Study: 22617578
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral contraceptive pills (gestodene 0.075 mg and ethinyl estradiol 20 microgram) for 6 months
Study: 22617578
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral contraceptive pills
Study: 22617578
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral contraceptive pills
Study: 20223838
Drug: Methylprednisolone (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (120 mg intramuscular injection)
Study: 11144061
Drug: Treatment (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specific treatment details not provided)
Study: 8809925
Drug: Low-dosage or
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage or short-time exercise programs
Study: 12854476
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion
Study: 6332953
Drug: Propranolol 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 0.05 mg/kg administered 4 to 5 minutes before aortic cross‐clamping
Study: 29725956
Drug: Sacchaflor (S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacchaflor (S. boulardii 5 × 10^9, Pharmaforce ApS) twice daily
Study: 26956679
Drug: Culturally informed
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally informed intervention including regular postcards, problem solving therapy, patient support, risk management, improved access to primary care, and cultural assessment in addition to usual care.
Study: 22499404
Drug: conventional Chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional Chest Physical therapy (cCPT)
Study: 20042424
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment only (Control group)
Study: 23551402
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg/kg) for 4 weeks
Study: 813951
Drug: Ibuprofen total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen total daily dose 1,200 mg
Study: 813951
Drug: Warfarin 7.5
Normalized name: warfarin 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 7.5 mg
Study: 23660437
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of the DRD2 agonist bromocriptine
Study: 21221531
Drug: Varenicline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 2 mg daily (extended 4-week pretreatment)
Study: 21221531
Drug: Usual 1-week
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual 1-week pretreatment (placebo lead in followed by active medication)
Study: 8757207
Drug: Double-strength beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-strength beclomethasone dipropionate (BDP-ds) aqueous nasal spray (84 micrograms/spray), once daily
Study: 2997101
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir 250 mg/m2 once daily for four weeks
Study: 2997101
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir 250 mg/m2 once daily
Study: 31420703
Drug: Cinnarizine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (25 mg) plus Betahistine (8 mg) combination, administered three times a day for 1 week
Study: 15237711
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog treatment (triptorelin or leuprolide acetate)
Study: 28012176
Drug: UE2343 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: UE2343 (10 mg and above)
Study: 25889354
Drug: Low-protein pancake
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein pancake breakfast (3 g protein)
Study: 11350703
Drug: Paroxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10 mg to 40 mg per day)
Study: 11350703
Drug: Problem‐Solving Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem‐Solving Treatment for Primary Care (PST‐PC)
Study: 11550739
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions
Study: 3370061
Drug: Torasemide 2.5
Normalized name: Torasemide 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 2.5 mg
Study: 3608350
Drug: Torasemide 5
Normalized name: Torasemide 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 5 mg
Study: 3608350
Drug: Torasemide 10
Normalized name: Torasemide 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 10 mg
Study: 3780838
Drug: Torasemide 20
Normalized name: Torasemide 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 20 mg
Study: 3370061
Drug: Torasemide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (all doses)
Study: 22494567
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day
Study: 18675477
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor (G-CSF) administration
Study: 18675477
Drug: G-CSF associated
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF associated to BMSC intracoronary infusion
Study: 19004228
Drug: AD (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD (combined therapy)
Study: 10421834
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) treatment in allergic asthmatic patients
Study: 10421834
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) treatment in COPD patients
Study: 27439370
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg
Study: 7617857
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormonal replacement therapy (HRT)
Study: 2213552
Drug: Sulindac, 200
Normalized name: Sulindac, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac, 200 mg daily for 1 week
Study: 20014253
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment (635 nm, 17.5 mW, 3 times per week for 2 weeks)
Study: 27590454
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser treatment
Study: 14583848
Drug: L-glutamine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine 30 g/day
Study: 11054630
Drug: Dipyridamole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.5 mg/kg body weight, intracoronary)
Study: 8686403
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with biochemical modulators
Study: 26636423
Drug: Exenatide +
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide + L-NMMA
Study: 22348319
Drug: Breath-actuated nebulizer
Normalized name: beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath-actuated nebulizer (BAN) delivering albuterol 2.5 mg or albuterol 2.5 mg plus ipratropium 0.25 mg
Study: 22348319
Drug: Standard nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nebulizer delivering albuterol 2.5 mg or albuterol plus ipratropium 0.5 mg
Study: 17244215
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% once daily
Study: 11382623
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% twice daily
Study: 8165534
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 ml administered through nasogastric tube)